Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-weekly cemiplimab for locally advanced basal cell carcinoma
ISRCTN10511385Phase 2Active, not recruiting
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in basal cell carcinoma (BCC), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Objective response rate at 6 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on ISRCTN10511385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10511385.